Pilot Neoadjuvant Trial with Combination of Lapatinib and Nab-Paclitaxel in HER2+Breast Cancer

被引：0
|
作者：
Kaklamani, V [1 ]
Uthe, R. [1 ]
Khan, S. [1 ]
Hansen, N. [1 ]
Bethke, K. [1 ]
Jeruss, J. [1 ]
Cianfrocca, M. [1 ]
Von Roenn, J. [1 ]
Rosen, S. [1 ]
Gradishar, W. [1 ]
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：568S / 568S
页数：1
相关论文
共 50 条
  • [21] Camrelizumab in Combination with Nab-Paclitaxel and Carboplatin versus Nab-Paclitaxel and Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer: A Multicenter, Open-Label, Randomized Controlled Study
    Zhao, Weipeng
    Wang, Xin
    Zhang, Bin
    Shi, Yehui
    Wang, Chen
    Wang, Xu
    Li, Shufen
    Hao, Chunfang
    Lu, Ning
    Jia, Yongsheng
    Zhang, Li
    Zhang, Lan
    Sun, Weixin
    Cao, Xuchen
    Tong, Zhongsheng
    CANCER RESEARCH, 2024, 84 (09)
  • [22] nab-Paclitaxel dose and schedule in breast cancer
    Martin, Miguel
    BREAST CANCER RESEARCH, 2015, 17
  • [23] nab-Paclitaxel dose and schedule in breast cancer
    Miguel Martín
    Breast Cancer Research, 17
  • [24] Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+locally advanced breast cancer with SPARC correlatives
    Yardley, D. A.
    Raefsky, E.
    Castillo, R.
    Lahiry, A.
    LoCicero, R.
    Thompson, D.
    Shastry, M.
    Trieu, V.
    Knauer, D.
    Desai, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care (vol 17, pg 265, 2016)
    Neoadjuvant, Colleoni M.
    LANCET ONCOLOGY, 2016, 17 (03): : E90 - E90
  • [26] A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
    Zeng, Tianyu
    Wang, Jue
    Li, Wei
    Sun, Chunxiao
    Yang, Fan
    Liang, Yan
    Fu, Ziyi
    Zha, Xiaoming
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2022, 33 : S492 - S492
  • [27] Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer
    Yuan, Y.
    Frankel, P.
    Li, M.
    Kruper, L.
    Jones, V.
    Treece, T.
    Waisman, J.
    Yim, J.
    Tumyan, L.
    Schmolze, D.
    Hurria, A.
    Yeon, C.
    Mortimer, J.
    Somlo, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [28] nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer
    Megerdichian, Christine
    Olimpiadi, Yuliya
    Hurvitz, Sara A.
    CANCER TREATMENT REVIEWS, 2014, 40 (05) : 614 - 625
  • [29] Phase II trial of lapatinib for brain metastases in patients with HER2+breast cancer.
    Lin, N. U.
    Carey, L. A.
    Liu, M. C.
    Younger, J.
    Come, S. E.
    Bullitt, E.
    Van den Abbeele, A. D.
    Li, X.
    Hochberg, F. H.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 3S - 3S
  • [30] Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study)
    Patel, Tejal Amar
    Ensor, Joe
    Creamer, Sarah
    Rodriguez, Angel Augusto
    Niravath, Polly Ann
    Darcourt, Jorge German
    Kaklamani, Virginia G.
    Meisel, Jane Lowe
    Li, Xiaoxian
    Kuhn, John G.
    Rosato, Roberto R.
    Belcheva, Anna
    Boone, Toniva
    Chang, Jenny Chee Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345